The BROADEN study (A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy) which was the largest global double blinded placebo controlled study published in 2022 demonstrated that treatment with volanesorsen (ISIS 304801/ISIS-APOCIIIRx/IONIS-APOCIIIRx, Waylivra®, Akcea/Ionis), an antisense oligonucleotide to apo-CIII, reduced serum triglyceride levels by more than 88% from baseline at 3 months and improved hepatic steatosis by 53% at month 12 with volanesorsen versus placebo (142). Here, APOC3 is linked to fatty liver disease.